Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: END033
MIFTS: 57

Endocarditis

Categories: Blood diseases, Cardiovascular diseases, Immune diseases, Infectious diseases, Respiratory diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Endocarditis

About this section

MalaCards integrated aliases for Endocarditis:

IMPROVED
Name: Endocarditis 11 75 53 41 43 14 63 16 71

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Cardiovascular diseases Respiratory diseases Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:10314
ICD9CM 34 421.9
MeSH 43 D004696
SNOMED-CT 68 56819008 91357005
ICD10 31 I33.9
UMLS 71 C0014118 C0375268
Sources

Summaries for Endocarditis

About this section

MedlinePlus: 41 What is endocarditis? Endocarditis is sometimes called infective endocarditis. It's a rare, but life-threatening inflammation of the lining inside your heart's chambers and valves (the endocardium). Endocarditis is usually caused by germs that get into your bloodstream and travel to your heart. Once they get inside your heart, the germs can attach to the lining or get trapped in the valves. They start to grow, causing an infection. If not treated quickly, the infection can cause damage to the heart and lead to serious health problems. What causes endocarditis? Bacterial infections cause most endocarditis. Normally, many bacteria live in your mouth, on your skin, or in other parts of the body. Sometimes the bacteria can get into your bloodstream from injuries such cuts or scrapes. Dental work and certain surgeries can also allow small amounts of bacteria to enter your bloodstream. In some cases, fungal infections cause endocarditis. The fungi, such as yeast, can live in parts of your body. Fungal infections generally happen in people who have weakened immune systems that can't stop the fungus from growing. This includes people who have HIV/AIDS. Who is more likely to develop endocarditis? In general, endocarditis is rare. If you're healthy, your immune system usually destroys the germs in your bloodstream before they can cause harm. But your chance of developing endocarditis may be higher than most people if you: Have certain heart conditions. Damaged or abnormal heart tissue and devices in your heart can trap germs more easily than healthy heart tissue. That means your risk of endocarditis is higher if you have: Heart valve disease. Certain congenital heart defects. A pacemaker or an implantable defibrillator. A heart valve replacement. Are older. Age-related changes to the heart valves, such as mitral valve prolapse or calcium deposits in the aortic valve, create places for germs to attach to the heart. Inject illegal drugs. Unclean needles may carry bacteria into the bloodstream. Have a condition that weakens your immune system. Don't take care of your teeth and gums. Poor dental health makes it easier for germs to get into your bloodstream through your gums and mouth. Have a long-term central venous line, a tube that stays in a large vein for weeks or months for medical treatment. Have already had endocarditis. Endocarditis can damage heart tissue, which increases your risk of getting it again. What are the symptoms of endocarditis? Endocarditis symptoms may be severe or very mild. They may start suddenly or slowly. And they can vary from person to person. The possible symptoms of endocarditis include: Fever and chills New or worsening heart murmur (an unusual sound heard between heartbeats) Chest pain Cough Muscle, joint, and back pain Night sweats (heavy sweating during sleep) Shortness of breath (feeling like you can't get enough air) Skin changes, including: Broken blood vessels Painful red or purple bumps Painless flat red spots on the palms of your hands or soles of your feet What other problems can endocarditis cause? When the germs are in your heart, they can clump together with blood cells. These clumps can break off and travel through your bloodstream. They may block blood flow, spread infection, or damage your organs, including your brain, lungs, kidneys, and spleen. Endocarditis may sometimes lead to sepsis, a medical emergency that happens when your body has an extreme response to the infection. Endocarditis can also cause serious heart problems including: Heart valve damage Heart failure Arrhythmia (a problem with the rate or rhythm of your heartbeat) How is endocarditis diagnosed? To find out if you have endocarditis, your doctor will: Ask about your medical history, including your symptoms, recent illnesses, and other health conditions that affect your chance of developing endocarditis. Do a physical exam. Likely order tests, such as: Blood tests to check for signs of infection, bacteria, or fungi in your blood. Chest x-rays. Heart tests. What are the treatments for endocarditis? If you have endocarditis, it's important to get treatment quickly. Treatments may include: Medicines Antibiotics to treat bacterial infections. Antibiotics are usually started through an intravenous (IV) line in the hospital. Antifungal medicine to treat fungal infections. Your doctor may suggest taking antifungal medicine for the rest of your life to prevent the infection from coming back. Heart surgery may be needed to repair or replace damaged valves and heart tissue. Surgery may also be done to remove infected tissue. Dental care, especially cleanings, can help reduce the amount of bacteria that grows in your mouth. Treatment may last weeks, and you may need tests to make sure it's working. Your doctor will also check you for problems that could develop from endocarditis, such as heart failure or an irregular heartbeat. Can endocarditis be prevented? If you have a higher chance of developing endocarditis than most people, you can reduce your risk if you: Take good care of your teeth and gums every day Have dental exams and cleaning at your dentist's office every 6 months Make heart-healthy habits part of your daily life to help prevent heart disease Call your health care provider right away if you have symptoms that could be endocarditis People with the highest risk for bacterial endocarditis need antibiotics before dental visits or certain medical or surgical procedures. Ask your provider if you're part of the highest risk group. If so, let all your providers know about your risk. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Endocarditis is related to infective endocarditis and libman-sacks endocarditis, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Endocarditis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Complement cascade and Overview of interferons-mediated signaling pathway. The drugs Imipenem and Ceftriaxone have been mentioned in the context of this disorder. Affiliated tissues include heart, spleen and skin, and related phenotypes are no effect and no effect

PubMed Health : 63 Endocarditis: Endocarditis (EN-do-kar-DI-tis) is an infection of the inner lining of the heart chambers and valves. This lining is called the endocardium (en-do-KAR-de-um). The condition also is called infective endocarditis (IE). The term "endocarditis" also is used to describe an inflammation of the endocardium due to other conditions. This article only discusses endocarditis related to infection. IE occurs if bacteria, fungi, or other germs invade your bloodstream and attach to abnormal areas of your heart. The infection can damage your heart and cause serious and sometimes fatal complications. IE can develop quickly or slowly; it depends on what type of germ is causing it and whether you have an underlying heart problem. When IE develops quickly, it's called acute infective endocarditis. When it develops slowly, it's called subacute infective endocarditis.

Disease Ontology: 11 A endocardium disease characterized by inflammation of the endocardium of the heart chambers and valves.

Wikipedia: 75 Endocarditis is an inflammation of the inner layer of the heart, the endocardium. It usually involves... more...
Sources

Related Diseases for Endocarditis

About this section

Diseases in the Endocarditis family:

Subacute Bacterial Endocarditis

Diseases related to Endocarditis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1766)
# Related Disease Score Top Affiliating Genes
1 infective endocarditis 33.4 IL6 GP1BA F2 CXCL8 CRP ALB
2 libman-sacks endocarditis 33.0 F2 CRP APOH
3 nonbacterial thrombotic endocarditis 32.9 SERPINC1 PLAT F2 CRP APOH
4 heart valve disease 32.2 TNNI3 IL6 F2 CRP APOH ALB
5 aortic valve insufficiency 32.0 TNNI3 F2 CRP ALB
6 mitral valve insufficiency 32.0 TNNI3 F2 CRP ALB
7 heart septal defect 32.0 SERPINC1 F2 CRP
8 brucellosis 31.8 TNF IL6 IL17A IL10 IFNG CXCL8
9 congestive heart failure 31.7 TNNI3 TNF IL6 ALB
10 q fever 31.7 TNF TLR2 IL6 IL10 IFNG
11 glomerulonephritis 31.6 TNF IL6 IL10 CRP ALB
12 rheumatic heart disease 31.5 TNF TLR2 IL6 IL17A IL10
13 acute kidney failure 31.5 PIK3C2A IL6 F2 ALB
14 rheumatic fever 31.4 TNF TLR2 IL6 IL10 IFNG ALB
15 tricuspid valve insufficiency 31.4 TNNI3 PLAT F2 CRP ALB
16 hypereosinophilic syndrome 31.4 IL10 IFNG EPX CXCL8
17 atrioventricular block 31.4 TNNI3 PIK3C2A CRP
18 cardiogenic shock 31.3 PLAT PIK3C2A
19 splenic abscess 31.3 F2 CRP ALB
20 pericarditis 31.3 TNNI3 TNF IL6 IFNG CXCL8 CRP
21 toxic shock syndrome 31.3 TNF TLR2 SERPINC1 IL6 IL10 IFNG
22 aspergillosis 31.3 TNF TLR2 IL6 IL10 IFNG EPX
23 splenic infarction 31.3 SERPINC1 F2 CRP APOH ALB
24 pulmonary embolism 31.2 TNNI3 SERPINC1 PLAT GP1BA F2 CRP
25 osteomyelitis 31.2 TNF TLR2 IL6 IL10 IFNG CXCL8
26 intracranial embolism 31.2 SERPINC1 PLAT IL6 F2 CRP ALB
27 alcohol use disorder 31.2 TNF IL6 F2 CRP ALB
28 mitral valve stenosis 31.2 SERPINC1 PLAT F2 CRP ALB
29 patent ductus arteriosus 1 31.2 IL6 F2 CXCL8 CRP ALB
30 whipple disease 31.2 TNF HSPD1 CRP ALB
31 hypertrophic cardiomyopathy 31.2 TNNI3 TNF IL6 CRP ALB
32 mitral valve disease 31.1 TNNI3 SERPINC1 IL6 F2 CRP ALB
33 endomyocardial fibrosis 31.1 TNF IL10 EPX
34 antiphospholipid syndrome 31.1 TNF SERPINC1 PLAT GP1BA F2 CRP
35 atrial heart septal defect 31.1 TNNI3 SERPINC1 PLAT F2 CRP ALB
36 endophthalmitis 31.1 TNF TLR2 IL6 CXCL8 CRP ALB
37 chronic kidney disease 31.1 TNNI3 TNF IL6 CRP ALB
38 crescentic glomerulonephritis 31.0 TNF IL17A CRP ALB
39 haemophilus influenzae 31.0 TNF TLR2 LACTB CXCL8
40 vasculitis 31.0 TNF IL6 IL17A IL10 HSPD1 CXCL8
41 vascular disease 31.0 TNF SERPINC1 PLAT IL6 HSPD1 GP1BA
42 stroke, ischemic 31.0 TNF SERPINC1 PLAT IL6 GP1BA F2
43 urinary tract infection 31.0 TNF TLR2 IL6 IL10 F2 CXCL8
44 aortitis 31.0 TNF IL6 IL17A IFNG CRP
45 intracranial abscess 31.0 LACTB CRP
46 polyarteritis nodosa 31.0 TNF IL6 CRP APOH
47 aortic dissection 31.0 TNNI3 IL6 F2 CRP ALB
48 mycobacterium fortuitum 31.0 LACTB HSPD1
49 pericardial effusion 31.0 TNNI3 TNF PIK3C2A IL6 F2 CRP
50 liver cirrhosis 31.0 TNF TLR2 SERPINC1 IL6 F2 ALB

Graphical network of the top 20 diseases related to Endocarditis:



Diseases related to Endocarditis
Sources

Symptoms & Phenotypes for Endocarditis

About this section

UMLS symptoms related to Endocarditis:


angina pectoris; chest pain; edema

GenomeRNAi Phenotypes related to Endocarditis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 ALB APOH CRP CXCL8 EPX F2
2 no effect GR00402-S-2 10.18 ALB APOH CRP EPX F2 GP1BA
3 Reduced mammosphere formation GR00396-S 9.56 ALB CXCL8 GP1BA HSPD1 IL17A PIK3C2A

MGI Mouse Phenotypes related to Endocarditis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 ALB APOH CRP EPX F2 GP1BA
2 muscle MP:0005369 10.22 ALB F2 HSPD1 IFNG IL10 IL6
3 cardiovascular system MP:0005385 10.17 ALB CRP F2 HSPD1 IFNG IL10
4 cellular MP:0005384 10.15 ALB F2 GP1BA HSPD1 IFNG IL10
5 immune system MP:0005387 10.1 ALB CRP EPX F2 IFNG IL10
6 liver/biliary system MP:0005370 10.06 ALB IFNG IL10 IL17A IL6 SERPINC1
7 digestive/alimentary MP:0005381 10.06 ALB F2 IFNG IL10 IL17A IL6
8 respiratory system MP:0005388 9.85 F2 HSPD1 IFNG IL10 IL17A IL6
9 hematopoietic system MP:0005397 9.8 EPX F2 GP1BA HSPD1 IFNG IL10
10 mortality/aging MP:0010768 9.5 ALB APOH F2 HSPD1 IFNG IL10
Sources

Drugs & Therapeutics for Endocarditis

About this section

PubMed Health treatment related to Endocarditis: 63

Infective endocarditis (IE) is treated with antibiotics and sometimes with heart surgery .

Drugs for Endocarditis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
2
Ceftriaxone Approved Phase 4 73384-59-5 5479530
3
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
4
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
5
Oxacillin Approved, Investigational Phase 4 66-79-5 6196
6
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
7
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
8
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
9
Moxifloxacin Approved, Investigational Phase 4 186826-86-8, 354812-41-2, 151096-09-2 152946
10
Tedizolid Approved, Investigational Phase 4 856866-72-3
11
Fusidic acid Approved, Investigational Phase 4 6990-06-3 3000226
12
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
13
Sulfamethoxazole Approved Phase 4 723-46-6 5329
14
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
15
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
16
Cefaclor Approved Phase 4 53994-73-3 51039
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18
Ethinylestradiol Approved Phase 4 57-63-6 5991
19
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
20
Polyestradiol phosphate Approved Phase 4 28014-46-2
21
Rifampicin Approved Phase 4 13292-46-1 135512673 5381226 135900090
22
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
23
Ofloxacin Approved Phase 4 82419-36-1 4583
24
Dicloxacillin Approved, Investigational, Vet_approved Phase 4 3116-76-5 18381
25
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
26
Meticillin Approved, Investigational Phase 4 61-32-5 6087
27
Vancomycin Approved Phase 4 1404-90-6 14969
28
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
29
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
30
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
31
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3 72562361
32
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
34 Anesthetics Phase 4
35 Contraceptives, Oral, Combined Phase 4
36 Contraceptives, Oral Phase 4
37 Contraceptive Agents Phase 4
38 Cytochrome P-450 Enzyme Inhibitors Phase 4
39
Clindamycin phosphate Phase 4 32603
40 Clindamycin palmitate Phase 4
41 Folic Acid Antagonists Phase 4
42 Folate Phase 4
43 Antitubercular Agents Phase 4
44 Estradiol 3-benzoate Phase 4
45 Antimalarials Phase 4
46 Estradiol 17 beta-cypionate Phase 4
47 Vitamin B9 Phase 4
48 Antiprotozoal Agents Phase 4
49 Antiparasitic Agents Phase 4
50 Vitamin B Complex Phase 4

Interventional clinical trials:

(show top 50) (show all 131)
# Name Status NCT ID Phase Drugs
1 Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study: a Multicenter, Prospective, Randomized Trial Comparing the State-of-the-Art Therapeutic Strategy Versus Early Surgery Strategy in Infective Endocarditis Unknown status NCT00624091 Phase 4
2 The Value of 99mTc-Leukoscan® Scintigraphy in the Diagnosis of Infectious Endocarditis on Surgical Materials Unknown status NCT03112356 Phase 4 99mTc-Leukoscan® scintigraphy
3 Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin in the Treatment of Methicillin-resistant Staphylococcus Aureus（MRSA） Blood Stream Infection (Septicemia) and Endocarditis in Chinese Patients Unknown status NCT02443064 Phase 4 Vancomycin
4 A Randomized Comparison of Early Surgery Versus Conventional Treatment Strategy in Patients With High Embolic Risk of Infective Endocarditis Completed NCT00750373 Phase 4
5 Evaluation of the Efficacy and Safety of Fosfomycin Plus Imipenem for the Treatment of Methicillin-resistant Staphylococcus Aureus (MRSA) Infective Endocarditis. Completed NCT00871104 Phase 4 Fosfomycin and imipenem;Vancomycin
6 Partial Oral Treatment of Endocarditis Completed NCT01375257 Phase 4 Oral treatment with antibiotics for endocarditis;Guideline treatment with parenteral antibiotics
7 Health Economic Evaluation of Rapid Detection of Bacteraemia and Fungemia by Real Time PCR for Cases of Febrile Neutropenia, Suspicion of Endocarditis and Severe Sepsis in Intensive Care Units Completed NCT00709358 Phase 4
8 The Effect of Sodium Bicarbonate on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery Completed NCT01920126 Phase 4 sodium bicarbonate;Saline
9 Short-course Antibiotic Regimen Compared to Conventional Antibiotic Treatment for Gram-positive Cocci Infective Endocarditis: Randomized Clinical Trial Recruiting NCT04222257 Phase 4 Antibiotics
10 Accelerated Treatment of Endocarditis Recruiting NCT05144399 Phase 4
11 Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) Recruiting NCT05156437 Phase 4 Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin;Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
12 Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis Not yet recruiting NCT05398679 Phase 4 Cefaclor;Ciprofloxacin Tablets;Ciprofloxacin Injection;Clindamycin Oral Capsule;Clindamycin Injection;Dicloxacillin Oral Capsule;Dicloxacillin;Fusidic Acid Only Product in Oral Dose Form;Fusidic Acid Only Product in Parenteral Dose Form;Levofloxacin Oral Tablet;Levofloxacin Injection;Linezolid Oral Tablet;Linezolid Injectable Product;Moxifloxacin tablet;Moxifloxacin Injectable Product;Rifampicin Only Product in Oral Dose Form;Rifampicin Only Product in Parenteral Dose Form;Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim];Sulfamethoxazole / Trimethoprim Injectable Product;Tedizolid Oral Tablet;Tedizolid Injection;Amoxicillin Capsules;Amoxicillin;Cefaclor Capsules
13 Four-week Duration Versus 6-week Duration of Therapy for the Treatment of Enterococcal Endocarditis Not yet recruiting NCT05398289 Phase 4 4-week duration of antibiotic therapy;6-week duration of antibiotic therapy
14 A Phase 4 Multicenter, Randomized, Double Blind Study to Describe the Efficacy and Safety of Cubicin® (Daptomycin for Injection) With and Without Initial Gentamicin Combination Therapy in the Treatment of S. Aureus Infective Endocarditis Terminated NCT00638157 Phase 4 daptomycin;daptomycin and gentamicin
15 Open Label Study to Assess the Efficacy and Safety of Daptomycin in Combination With Anti-Cell Wall Active Therapy in the Treatment of Enterococcal Endocarditis Terminated NCT00401960 Phase 4 Daptomycin
16 Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Terminated NCT01734694 Phase 4 Vancomycin;Ceftaroline;Daptomycin;Linezolid
17 An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Terminated NCT02783404 Phase 4 Amoxicillin;Amoxicillin-Potassium Clavulanate
18 A Pilot Proof of Concept Single-Center Study of the Use of Oritavancin in Systemic Staphylococcus Aureus Infections in Patients With Opioid Use Disorder Withdrawn NCT03761953 Phase 4 Oritavancin Injection
19 A Phase 3, Multicenter, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of Daptomycin Compared to Conventional Therapy In the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to Staph Aureus Completed NCT00093067 Phase 3 daptomycin
20 A Phase III Randomized, Open-labeled Clinical Trial of MK-3009 (Daptomycin) in Patients With Skin and Soft Tissue Infections, Septicemia and Right-sided Infective Endocarditis Caused by MRSA Completed NCT00770341 Phase 3 Daptomycin 4 mg/kg;Comparator: vancomycin;Daptomycin 6 mg/kg
21 Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure Completed NCT02142075 Phase 3 Daptomycin
22 A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis Completed NCT03138733 Phase 3 Ceftobiprole medocaril;Daptomycin
23 Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus (Relais Oral Dans le Traitement Des Endocardites à Staphylocoques Multi-sensibles) Recruiting NCT02701608 Phase 3 Levofloxacin;Rifampicin
24 Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus (Relais Oral Dans le Traitement Des Endocardites à Streptocoques Multi-sensibles) Recruiting NCT02701595 Phase 3 Amoxicillin
25 A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis Terminated NCT02208063 Phase 3 Telavancin;Vancomycin;Daptomycin;Synthetic penicillin;Cefazolin
26 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis Terminated NCT04160468 Phase 3 Exebacase;Placebo
27 Phase II Clinical Trial to Evaluate an Antibiotic Regimen Pharmacokinetic Applicable to Outpatient Parenteral Antimicrobial Therapy in Enterococcus Faecalis Infective Endocarditis Unknown status NCT03681431 Phase 2 Ceftriaxone 4g/ 24h;Ceftriaxone 2g/ 12h
28 A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for the Treatment of Adult Patients With Staphylococcus Aureus Bloodstream Infections (Bacteremia) Including Endocarditis Completed NCT03163446 Phase 2 Placebo
29 Hyperbaric Oxygen Treatment in Humans With Gram Positive Cocci Endocarditis" Recruiting NCT04691440 Phase 2 Hyperbaric oxygen
30 Early Feasibility Study of Somatostatin Receptors PET Imaging (68Ga-DOTATOC PET/CT) for the Diagnosis of Infective Endocarditis Not yet recruiting NCT05183555 Phase 2 68Ga-DOTATOC PET/CT
31 Contribution of PET/CT With Gallium 68 Citrate (68Ga-PET/CT) for the Diagnosis of Prosthetic Valve Infective Endocarditis Not yet recruiting NCT05446376 Phase 2 68Ga-citrate PET/CT
32 Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT) Not yet recruiting NCT04886284 Phase 2 Ertapenem;Placebo
33 A Phase 2 Multicenter, Randomized, Double-blinded, Study to Describe the Safety, Efficacy, and Pharmacokinetics of Daptomycin 10 mg/kg/Day and Vancomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Terminated NCT00695903 Phase 2 daptomycin;vancomycin
34 Phase 2, Open-Label, Randomized, Multicenter Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Documented Infective Endocarditis Terminated NCT03148756 Phase 2 Dalbavancin;Standard of Care
35 Evaluation de la rhAnnexine V-128 radiomarquée Dans le Diagnostic de l'Endocardite Infectieuse, du Thrombus Atrial et de Leurs Complications Emboliques associées Terminated NCT02459613 Phase 1, Phase 2 99mTc-Annexin V-128 SPECT
36 An Open-Label, Multiple-Ascending Dose, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LSVT-1701 as an Add-on to Standard of Care Antibiotics for the Treatment of Complicated Methicillin-Sensitive and -Resistant Staphylococcus Aureus Bacteremia Including Left- and Right-sided Infective Endocarditis Withdrawn NCT05329168 Phase 2 Tonabacase (LSVT-1701)
37 Gender Study on Predisposition to Infectious Endocarditis Unknown status NCT03979261
38 Effect of Dexmedetomidine on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery Unknown status NCT02698930 dexmedetomidine;Normal saline
39 Infective Endocarditis in Developing Countries, a Prospective, Observational, Multicentre Study Unknown status NCT02128139
40 Long-term Clinico-radiological Evolution of Patients With Symptomatic and Asymptomatic Brain Lesions During Infectious Endocarditis Unknown status NCT02252900
41 Beta-lactam Pharmacokinetic Profiles in Patients With Infective Endocarditis Unknown status NCT02033421
42 Molecular Imaging in Infective Endocarditis Using Hybrid Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR) and Computed Tomography (PET/CT) Unknown status NCT03626571
43 Detection of the Most Common Micro Organism of Infective Endocarditis in Assiut University Hospital Unknown status NCT03487653
44 Treatment of Infective Endocarditis by Vancomycin and Gentamycin in Assiut University Children Hospital Unknown status NCT03688659 Vancomycin and gentamycin
45 Etiology of Endocarditis in Negative Blood Cultures Unknown status NCT02816307
46 The Use of Cardiac Computarized Tomography in Infective Endocarditis Unknown status NCT00550823
47 NExt-Generation Sequencing and Cell Culture-based Characterization of S. Aureus in Infective Endocarditis Unknown status NCT04257292
48 Positron Emission Tomography Combined With Computed Tomography (PET CT) in Suspected Cardiovascular Implantable Electronic Device Infection, a Pilot Study - PET Guidance I Unknown status NCT02196753
49 Study of Leukocyte Immunophenotype and the Lipid Transport System as Predictive Biomarkers of Severe Bacterial Infections Unknown status NCT04178915
50 Study of Autoantibodies in Infective Endocarditis Unknown status NCT00562653

Search NIH Clinical Center for Endocarditis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


GENTAMICIN SULFATE PWDR

Cochrane evidence based reviews: endocarditis

Sources

Genetic Tests for Endocarditis

About this section
Sources

Anatomical Context for Endocarditis

About this section

Organs/tissues related to Endocarditis:

MalaCards : Heart, Spleen, Skin, Lung, Brain, Kidney, Endothelial
Sources

Publications for Endocarditis

About this section

Articles related to Endocarditis:

(show top 50) (show all 30001)
# Title Authors PMID Year
1
Construction and internal validation of a novel nomogram for predicting prognosis of infective endocarditis. 62 41
36241684 2022
2
Sex-related disparities in the incidence and outcomes of infective endocarditis according to type 2 diabetes mellitus status in Spain, 2016-2020. 62 41
36180922 2022
3
Should more patients be offered repair for mitral valve endocarditis? a single-centre 15-year experience. 62 41
36180915 2022
4
Fibronectin-binding proteins and clumping factor A in Staphylococcus aureus experimental endocarditis: FnBPA is sufficient to activate human endothelial cells. 53 62
17393025 2007
5
The contribution of gC1qR/p33 in infection and inflammation. 53 62
17544818 2007
6
Bartonella koehlerae, a new cat-associated agent of culture-negative human endocarditis. 53 62
15297484 2004
7
Virulence of enterococci. 53 62
7834601 1994
8
Haemophilus parainfluenzae endocarditis in a patient with mitral valve prolapse. 53 62
8323254 1993
9
Activity of ampicillin plus sulbactam against beta-lactamase producing enterococci in experimental endocarditis. 53 62
8444668 1993
10
Killing curve activity of ciprofloxacin is comparable to synergistic effect of beta-lactam-tobramycin combinations against Haemophilus species endocarditis strains. 53 62
1389104 1992
11
Thiocyanate is the major substrate for eosinophil peroxidase in physiologic fluids. Implications for cytotoxicity. 53 62
2002037 1991
12
Efficacy of amoxycillin/clavulanic acid in experimental Staphylococcus aureus endocarditis in the rat. 53 62
2050588 1991
13
Bromide-dependent toxicity of eosinophil peroxidase for endothelium and isolated working rat hearts: a model for eosinophilic endocarditis. 53 62
1985118 1991
14
Parental perceptions and experiences of an oral health care promotion intervention for children with congenital heart defects. 62
35549844 2022
15
Successful treatment of canine infective endocarditis caused by Bacillus amyloliquefaciens. 62
35068361 2022
16
Application of machine learning algorithms for localized syringe services program policy implementation - Florida, 2017. 62
35900201 2022
17
Streptococcus mutans PrsA mediates AtlA secretion contributing to extracellular DNA release and biofilm formation in the pathogenesis of infective endocarditis. 62
35876630 2022
18
Surgical versus medical treatment for infective endocarditis in patients on dialysis: a systematic review and meta-analysis. 62
35450507 2022
19
Long-term outcomes of mechanical versus biological valve prosthesis in native mitral valve infective endocarditis. 62
35652503 2022
20
Tricuspid Valve Endocarditis in Four Patients with Unrepaired Restrictive Perimembranous Ventricular Septal Defects. 62
35657420 2022
21
Endocarditis-associated rapidly progressive glomerulonephritis mimicking vasculitis: a diagnostic and treatment challenge. 62
35243934 2022
22
Repair versus replacement for active endocarditis of the mitral valve: 9 years of experience. 62
36073065 2022
23
Outcomes of Surgical Aortic Valve Replacement After Transcatheter Aortic Valve Implantation. 62
36075751 2022
24
Editorial commentary: Native mitral valve infective endocarditis-Surgical concerns? 62
36040687 2022
25
Ross procedure for acute infective endocarditis. 62
36116048 2022
26
Acinetobacterbaumannii-induced infective endocarditis: new insights into pathophysiology and antibiotic resistance mechanisms. 62
36111747 2022
27
Surgery for native pulmonary valve infective endocarditis: Known and unknown. 62
36064036 2022
28
The prevalence of persistent bacteraemia in patients with a non-staphylococcal infective endocarditis, a retrospective cohort study. 62
36002040 2022
29
Aortic root abscess from Enterococcus faecalis infective endocarditis: Case report and brief review of the literature. 62
36105831 2022
30
Celiac Trunk Mycotic Aneurysm: Diagnosis and Treatment of a Post-infective Endocarditis Complication. 62
35816434 2022
31
The clinical pattern differentiates ANCA-positive infective endocarditis patients from ANCA-associated vasculitis patients: a 23 years' retrospective cohort study in China and follow-ups. 62
35906495 2022
32
Injection drug induced septic embolism-A growing concern. 62
36188073 2022
33
Aortic root abscess and anomalous aortic origin of right coronary artery in a 5-year-old child. 62
36054378 2022
34
Occult Presentation of Infective Endocarditis in Systemic Lupus Erythematosus. 62
35939614 2022
35
Clinical Risk Factors for Infective Endocarditis Patients With Staphylococcus Aureus Bacteremia and the Diagnostic Utility of Transesophageal Echocardiogram. 62
35870547 2022
36
AngioVac for Vegetation Debulking in Right-sided Infective Endocarditis: A Systematic Review and Meta-Analysis. 62
35961428 2022
37
Impact of Opioid Epidemic on Infective Endocarditis Outcomes in the United States: From the National Readmission Database. 62
36085056 2022
38
Case Report: Use of Percutaneous Coronary Revascularization to Temporarily Stabilize a Patient With Streptococcus Viridans Bioprosthetic Aortic Valve Endocarditis Resulting in Non-Embolic Left Main Coronary Artery Obstruction. 62
35739014 2022
39
Management of Prosthetic Valve Endocarditis-Related Acute Coronary Syndrome: Which Strategy Is the Best? 62
35820997 2022
40
Long-term results of aortic root replacement for endocarditis. 62
35979690 2022
41
Reply to Letter to the Editor: Management of Prosthetic Valve Endocarditis-Related Acute Coronary Syndrome: Which Strategy Is the Best? 62
36058830 2022
42
Splenic Abscesses in Endocarditis: A Rare Disease with High Mortality. The Experience of a Heart Institute in Brazil. 62
36202396 2022
43
Endocarditis with disseminated thromboembolisms and hypercoagulable state. 62
36261310 2022
44
Integrated evaluation of tricuspid valve endocarditis and septic pulmonary embolism with transesophageal echocardiography. 62
35950344 2022
45
Expression of Concern for Prudent et al., "Fluorescence In Situ Hybridization (FISH) and Peptide Nucleic Acid Probe-Based FISH for Diagnosis of Q Fever Endocarditis and Vascular Infections". 62
36069599 2022
46
Abiotrophia defectiva Endocarditis With Septic Emboli and an Enlarging Subaortic Pseudoaneurysm: A Novel Application for Ferumoxytol Cardiac Magnetic Resonance. 62
35862017 2022
47
Surgical treatment of isolated tricuspid valve endocarditis: Midterm data. 62
35790024 2022
48
How to manage isolated tricuspid valve endocarditis utilizing cardiac surgery? 62
35870163 2022
49
A New Insight Into Nonbacterial Thrombotic Endocarditis: A Systematic Review of Cases. 62
36052565 2022
50
Percutaneous Debulking of Mitral Valve Nonbacterial Thrombotic Endocarditis. 62
36265944 2022
Sources

Variations for Endocarditis

About this section
Sources

Expression for Endocarditis

About this section
Search GEO for disease gene expression data for Endocarditis.
Sources

Pathways for Endocarditis

About this section

Pathways related to Endocarditis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Complement cascade 66
Show member pathways
 12.63 TLR2 IFNG F2 CRP ALB
2
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.63 TNF IL6 IL17A IL10 IFNG CXCL8
3
NF-kappaB Signaling 3
12.57 TNF TLR2 IL17A IL10 IFNG
4
Immune response IL-23 signaling pathway 22
Show member pathways
 12.55 TNF IL6 IL17A IL10 IFNG F2
5
Toll-Like receptor Signaling Pathways 65
Show member pathways
 12.51 TNF TLR2 IL6 CXCL8
6
Bacterial infections in CF airways 22
Show member pathways
 12.42 CXCL8 IFNG IL6 TLR2 TNF
7
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
Show member pathways
 12.37 SERPINC1 IL6 F2 ALB
8
Toll Comparative Pathway 64
Show member pathways
 12.31 TNF IL6 IFNG CXCL8
9
IL-17 Family Signaling Pathways 65
Show member pathways
 12.28 TNF TLR2 IL6 IL17A CXCL8
10
Colorectal Cancer Metastasis 64
12.2 IFNG IL6 TLR2 TNF
11
T-cell activation SARS-CoV-2 74
Show member pathways
 12.15 TNF IL17A IL10 IFNG
12
Sudden infant death syndrome (SIDS) susceptibility pathways 74
12.14 TNF IL6 IL10 HSPD1 CXCL8
13
Neuroinflammation and glutamatergic signaling 74
12.11 TNF IL6 IL10 IFNG
14
Spinal cord injury 74
12 TNF IL6 IFNG CXCL8
15
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.96 TNF IL6 IL10 IFNG GP1BA
16
Senescence and autophagy in cancer 74
11.95 PLAT IL6 IFNG CXCL8
17
Interleukin-4 and Interleukin-13 signaling 66
11.91 TNF IL6 IL17A IL10 CXCL8
18
Th17 Differentiation 65
Show member pathways
 11.87 TLR2 IL6 IL17A IFNG
19
Innate Lymphoid Cells Differentiation 65
11.81 TNF IL17A IL10 IFNG
20
Network map of SARS-CoV-2 signaling pathway 74
Show member pathways
 11.77 IL6 CXCL8 CRP
21
Glucocorticoid receptor regulatory network 61
11.77 IL6 IFNG CXCL8
22
Dendritic Cells Developmental Lineage Pathway 65
11.77 TNF IL6 IL10 IFNG
23
Allograft rejection 74
11.77 TNF IL17A IL10 IFNG CXCL8
24
Acute viral myocarditis 74
11.75 IFNG IL10 IL6
25
Burn wound healing 74
11.75 CXCL8 IL6 TNF
26
AP-1 transcription factor network 61
11.72 IL6 IL10 IFNG CXCL8
27
Th17 cell differentiation pathway 74
11.71 IL6 IL17A IFNG
28
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 61
Show member pathways
 11.7 TNF IFNG CXCL8
29
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.68 CXCL8 IFNG IL6 TNF
30
Lung fibrosis 74
11.67 TNF IL6 CXCL8
31
miRNAs involvement in the immune response in sepsis 74
11.66 TNF IL6 IL10 CXCL8
32
IL 10 signaling pathway 67
11.65 TNF PIK3C2A IL6 IL10
33
ATF-2 transcription factor network 61
11.62 IL6 IFNG CXCL8
34
SARS-CoV-2 innate immunity evasion and cell-specific immune response 74
11.57 TNF IL10 CXCL8
35
MSP-RON Signaling 64
11.54 TNF TLR2 IFNG
36
"Non-genomic actions of 1,25 dihydroxyvitamin D3" 74
11.53 TNF IL6 IFNG CXCL8
37
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.51 TNF IL6 IFNG
38
Extrafollicular B cell activation by SARS-CoV-2 74
11.51 TNF IL6 IL10 IFNG CRP
39
Fibrin complement receptor 3 signaling pathway 74
11.48 TNF PLAT IL6
40
Interleukin-10 signaling 66
11.48 CXCL8 IL10 IL6 TNF
41
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
Show member pathways
 11.39 IFNG IL10 TNF
42
IL-10 Pathway 64
11.37 TNF IL6 IL10
43
Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway 74
11.3 TNF IL6 CXCL8
44
amb2 Integrin signaling 61
11.27 TNF PLAT IL6
45
Development and heterogeneity of the ILC family 74
11.26 TNF IL6 IL17A IFNG
46
IL1 and megakaryocytes in obesity 74
11.17 TLR2 IFNG F2
47
Cytokines and inflammatory response 74
11.13 IFNG IL10 IL6 TNF
48
Inflammatory bowel disease signaling 74
Show member pathways
 11.12 TNF TLR2 IL6 IL10 IFNG
49
IL27-mediated signaling events 61
Show member pathways
 11.1 TNF TLR2 IL6 IL17A IL10 IFNG
50
Prostaglandin signaling 74
11.07 TNF IL6 IL17A CXCL8
Sources

GO Terms for Endocarditis

About this section

Cellular components related to Endocarditis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.07 ALB APOH CRP CXCL8 EPX F2
2 extracellular space GO:0005615 9.83 ALB APOH CRP CXCL8 EPX F2

Biological processes related to Endocarditis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.4 CRP CXCL8 IL17A IL6 TLR2 TNF
2 positive regulation of tumor necrosis factor production GO:0032760 10.21 TLR2 IL6 IL17A IFNG
3 blood coagulation GO:0007596 10.16 F2 GP1BA PLAT SERPINC1
4 immune response GO:0006955 10.15 TNF TLR2 IL6 IL17A IL10 IFNG
5 defense response to Gram-positive bacterium GO:0050830 10.13 TNF TLR2 IL6 IL17A CRP
6 positive regulation of interleukin-10 production GO:0032733 10.1 TLR2 IL6 HSPD1
7 acute-phase response GO:0006953 10.1 IL6 F2 CRP
8 liver regeneration GO:0097421 10.08 TNF IL6 IL10
9 positive regulation of interleukin-1 beta production GO:0032731 10.08 TNF IL6 IL17A IFNG
10 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.05 TNF IL6 IL17A
11 microglial cell activation GO:0001774 10.04 TNF TLR2 IFNG
12 positive regulation of osteoclast differentiation GO:0045672 10.02 TNF IL17A IFNG
13 fibrinolysis GO:0042730 9.99 F2 GP1BA PLAT
14 positive regulation of chemokine production GO:0032722 9.97 IFNG IL6 TLR2 TNF
15 negative regulation of cytokine production involved in immune response GO:0002719 9.93 TNF IL10
16 negative regulation of fibrinolysis GO:0051918 9.93 APOH F2 PLAT
17 positive regulation of interleukin-12 production GO:0032735 9.92 TLR2 IL17A IFNG HSPD1
18 positive regulation of nitrogen compound metabolic process GO:0051173 9.89 IFNG TNF
19 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.88 IFNG TNF
20 positive regulation of vitamin D biosynthetic process GO:0060557 9.84 TNF IFNG
21 chronic inflammatory response to antigenic stimulus GO:0002439 9.83 TNF IL10
22 response to molecule of bacterial origin GO:0002237 9.8 TLR2 IL10 CXCL8
23 hemostasis GO:0007599 9.79 SERPINC1 GP1BA F2
24 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 9.76 F2 IL10 IL6 TNF
25 negative regulation of lipid storage GO:0010888 9.73 TNF IL6 CRP
26 positive regulation of interleukin-6 production GO:0032755 9.73 TNF TLR2 IL6 IL17A IFNG HSPD1
27 regulation of blood coagulation GO:0030193 9.1 SERPINC1 GP1BA F2 APOH

Molecular functions related to Endocarditis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 9.43 TLR2 HSPD1 F2
2 cytokine activity GO:0005125 9.36 TNF IL6 IL17A IL10 IFNG CXCL8
Sources

Sources for Endocarditis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....